<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878680</url>
  </required_header>
  <id_info>
    <org_study_id>D2287R00142</org_study_id>
    <nct_id>NCT03878680</nct_id>
  </id_info>
  <brief_title>Prevalence of Asthma and Allergies Among Children in UAE</brief_title>
  <acronym>ISAAC-UAE</acronym>
  <official_title>Prevalence of Asthma and Allergies Among Children in UAE-A Cross-sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, cross-sectional study to recruit a random sample of 6000 children via school
      class registers: 3000 children aged 13-14 years and 3000 children aged 6-7 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, cross-sectional study to recruit a random sample of 6000 children via school
      class registers: 3000 children aged 13-14 years and 3000 children aged 6-7 years.Standard
      ISAAC core questions for wheezing, rhinitis, and atopic dermatitis will be used. The ISAAC
      questionnaire has been validated by the World Health Organization and translated into many
      languages, and used in many countries. In this study, the Arabic and English version will be
      used. In addition, questions regarding exposure to Arabian incense &quot;Bokhor&quot; and smoking
      questions of the environmental questionnaire will be included.

      ISAAC Questionnaires

        1. Core questionnaire on wheezing.

        2. Core questionnaire on rhinitis.

        3. Core questionnaire on atopic dermatitis.

        4. Smoking questions of the environmental questionnaire.

        5. Video questionnaire on wheezing (only for 13-14 years age group, if applicable)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of asthma in children aged 6-7 years and 13-14 years in Dubai and the Northern Emirates.</measure>
    <time_frame>3 Month</time_frame>
    <description>Through International study of Asthma and Allergies in Children(ISAAC)core questionnaire on Asthma and Wheezing: A set of 8 questions to address wheezing attacks, assessing the prevalence of wheezing illness, frequency of wheezing, diagnosis of asthma.Descriptive summaries of the data will be presented. Comparisons between different centers on the rates of events will be made using appropriate methods. Crude rates can be compared by using contingency tables or logistic regression. Comparison of standardized rates or data that needs controlling for confounding will require analysis by logistic regression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of asthma in children aged 6-7 years and 13-14 years in Dubai and the Northern Emirates.</measure>
    <time_frame>3 Month</time_frame>
    <description>Through International study of Asthma and Allergies in Children(ISAAC)core questionnaire on (a)Wheezing,(b)rhinitis and (c)atopic dermatitis.
Wheezing questionnaire:8 questions to address wheezing attacks, frequency, assessing prevalence illness, diagnosis of asthma.
Rhinitis questionnaire : 6 questions to addressing detection of rhinitis, detecting atopy among subjects with rhinitis , interference with daily activities.
Atopic Dermatitis questionnaire : 7 questions to addressing severity, rashes, and nonatopic forms of eczema.
Most of the questions used iare Binary questions Yes or NO .
Data from 6-7 year old and 13-14 year old analysis separately. Each measure of prevalence and severity will be compared between centres. The effect of cluster sampling by schools will considered in the analysis.
Basic descriptive summaries data will be compiled and presented for each condition, in both age groups, for males and females, from each centres.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Prevalence of asthma in children aged 6-7 years and 13-14 years in Dubai and the Northern Emirates, who were exposed to Arabian incense &quot;Bokhor&quot;.</measure>
    <time_frame>3 Month</time_frame>
    <description>Questionnaire of Exposer to Arabian incense &quot;Bokhor&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence of asthma in children aged 6-7 years and 13-14 years in Dubai and the Northern Emirates, who were exposed to tobacco smoke</measure>
    <time_frame>3 Month</time_frame>
    <description>Smoking questions of the environmental questionnaire</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3737</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>13-14 years age group</arm_group_label>
    <description>Children with age 13-14 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-7 years age goup</arm_group_label>
    <description>Children with age 6-7 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Study questionnaires</intervention_name>
    <description>Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:
Core questionnaire on wheezing.
Core questionnaire on rhinitis.
Core questionnaire on atopic dermatitis.</description>
    <arm_group_label>13-14 years age group</arm_group_label>
    <arm_group_label>6-7 years age goup</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with age 6-7 years or with age 13-14 years at the time of questionnaires
        completion, and residing in Dubai and the Northern Emirates of UAE
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with age 6 to 7 years or with age 13 to 14 years at the time of
             questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.

          -  Children aged 6 to 7 years or 13 to14 years, whose legal guardians give their consent.

          -  Able to give assent in the 13 to 14 years group.

          -  Able to comprehend and answer the questionnaire themselves in the 13 to 14 years
             group.

        Exclusion Criteria:

          -  Aged 13 to 14 years and unable to answer the questionnaire due to physical or mental
             disability.

          -  Parent or legal guardian refuses sign and return consent for the 6 to 7 years group
             and the 13 to 14 years group.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ajman</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>FUJ</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>RAK</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sharjah</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>UMQ</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D2287R00142&amp;amp;attachmentIdentifier=170b8f20-7342-4be5-8be3-1418920f8b17&amp;amp;fileName=4.0_ISAAC_D2287R00142_CSR_final_V1.0_(08Apr2020)_Docusign_Redacted_for_CT.Gov.pdf&amp;amp;versionIdentifier=</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

